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Systemic diseases characterized by elevated levels of C-reactive protein (CRP), such
as sepsis or systemic inflammatory response syndrome, are usually associated with
hardly controllable haemodynamic instability. We therefore investigated whether CRP
itself influences blood pressure and heart rate. Immediately after intravenous injection
of purified human CRP (3.5mg CRP/kg body weight) into anesthetized rabbits, blood
pressure dropped critically in all animals, while control animals injected with bovine serum
albumin showed no response. Heart rate did not change in either group. Approaching
this impact on a cellular level, we investigated the effect of CRP in cell lines expressing
adrenoceptors (CHO-α1A and DU-145). CRP caused a Ca2+ signaling being dependent
on the CRP dose. After complete activation of the adrenoceptors by agonists, CRP
caused additional intracellular Ca2+ mobilization. We assume that CRP interacts with
hitherto unknown structures on the surface of vital cells and thus interferes with the
desensitization of adrenoceptors.
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INTRODUCTION
C-reactive protein (CRP), a circulating acute-phase plasma protein, increases very rapidly and
at high serum concentrations in response to infection or tissue injury. It has a Ca2+-dependent
binding specificity for phosphocholine, which is widely distributed in polysaccharides of pathogens
and in cellular membranes (1). Thus, CRP is able to opsonize a number of pathogens as well
as membranes of damaged and necrotic cells, facilitates their removal and thereby also mediates
tissue damage by activating complement (2). It is commonly established both as a systemic and
non-specific marker of inflammatory processes and as a risk factor and mediator of cardiac events
(3–6). In addition, CRP has been shown to directly activate circulating leukocytes with subsequent
release of mediators that promote destabilization of intravascular plaques, thereby increasing the
risk of cardiovascular events (7).
While it has been shown that blood pressure, heart rate and catecholamines as well as adrenergic
receptors can affect circulating CRP concentrations, a systemic influence of CRP has hardly been
investigated so far. The use of beta-adrenoceptor (β-AR) blockers has been found to correlate
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with reduced circulating CRP levels, presumably due to a
reduction in shear stress on endothelial cells of the blood vessels
and thus a reduced inflammatory response (8–10). In contrast,
chronic stimulation of β-ARs and catecholamines triggers an
inflammatory response in hepatocytes and thus leads to an
increase in circulating CRP (11, 12). Furthermore, chronic,
moderate CRP levels are associated with general hypertension,
increased heart rate and increased pulse pressure (13, 14).
However, a direct influence of CRP on adrenergic receptors
resulting in acute effects on the cardiovascular system have not
yet been proven to be causal (13–15).
In the clinical situation, critically ill patients, suffering
from e.g., sepsis or acute pancreatitis often develop systemic
inflammatory response syndrome (SIRS) and are characterized
by hardly controllable hemodynamic variables such as low
mean arterial pressure (<70 mmHg) with subsequent reduced
organ perfusion and additionally elevated CRP levels (16). Both
parameters are independently associated with clinical outcome,
mortality and disease severity (17–19).
We investigated acute effects of infused CRP on the circulatory
system in vivo. We chose healthy rabbits, which express
comparable endogenous CRP levels as humans (rabbits:<3mg/L
baseline, >100 mg/L acute phase; humans: <1 mg/L baseline,
>500 mg/L acute phase) as animal model because the binding
activity of rabbit CRP is comparable to that of human CRP and
both play a similar biological role in the innate immune system
(20, 21). Furthermore, we investigated the influence of CRP on
signal transduction in vitro. We used cell models with expression
of α- and β-adrenergic receptors, which belong to the group of
G protein-coupled receptors (GPCRs) but may have different
pathways of signal transduction. Activation of α1-adrenergic
receptors results in a Ca2+ release from the intracellular Ca2+
storage in the endoplasmic reticulum. The activation of β1- and
β2-ARs leads to the opening of voltage-gated Ca
2+ channels and
thus to an influx of external Ca2+ across the plasma membrane.
Changes in the intracellular free Ca2+ concentration can be
observed and quantified by ratiometric fluorescence (22).
Ca2+ as an essential second messenger in intracellular signal
transduction pathways plays a key role in the control of
various cellular functions such as contraction, proliferation and
transcription (23). For the first time, we report a direct effect of
CRP on the Ca2+-signaling in two different cell lines.
ANIMALS, MATERIALS, AND METHODS
Preparation of Purified Human CRP
Human plasma samples were collected from patients with high
CRP concentrations, pooled and stored frozen at −20◦C until
the experiments began. Plasma pool was thawed, and CRP was
purified by running an affinity chromatography column of a
selective CRP-binding matrix (Pentracor GmbH, Germany) (24).
Elution of CRP was performed by an elution buffer consisting
of 0.1M Tris, 0.2M NaCl, and 2mM EDTA, pH 8, which
inhibited the Ca2+-dependent binding of CRP to the matrix.
The wash fractions were collected. After determining the CRP
concentration via ELISA, the fractions were centrifuged over
a molecular cut-off filter of 50 kDa in order to concentrate
pentameric CRP and to exchange the buffer system. CRP was
then diluted in application buffer (NaCl 0.9%, Tris 10µM,
EDTA 20µM, Pluronic 1 g/L) to a final concentration of 15
mg/mL. In order to keep possible endotoxin contamination as
low as possible, we used a sterile CRP adsorber, treated the
devices with NaOH or depyrogenated the glass devices at 220◦C,
prepared everything with sterile cell culture water and used
sterile endotoxin free disposable material. Before elution we
washed several times. After elution we concentrated the CRP by
ultracentrifugation and collected it in fresh sterile buffer.
Animals
Seven female New Zealand White rabbits were purchased from
Harlan Winkelmann with either 3 kg or at 8–10 weeks age. At
the time point of the experiment, 3 animals were ∼24 weeks
old (4.3–5.3 kg) and 4 animals were ∼10 weeks old (1.85–
1.95 kg). All rabbits were housed in groups of five and according
to FELASA guidelines. Health monitoring at the commercial
breeder followed the FELASA recommendations. The study
protocol (Reg. No.: G0299/09) was approved by the University
Animal Care Committee and the federal authorities for animal
research in Berlin, Germany.
Injection of CRP in Rabbits (in vivo)
On the day of the experiment, rabbits were anesthetized
intramuscularly with a mixture of 35 mg/kg ketamine
(Ursotamin, Serumwerk Bernburg, Germany), 0.25 mg/kg
medetomidine (Domitor, Pfizer, USA) and 0.1 mg/kg atropine
(Atropinsulfat B.Braun, B.Braun, Germany), followed by
inhalation of 1.1 Vol.% isoflurane (Forene, Abbott, USA) via
mask. This was according to standard practice guidelines (25). A
catheter (Vygonule, B. Braun, Germany) was inserted in an ear
artery for continuous measurement of the mean arterial blood
pressure (ABP) and the heart rate (HR) using the monitoring
system HP Model 66S. Data points were recorded every 20ms.
For later analysis of ABP and HR the analog output-signal
of the monitor was transformed into digital signals (HB627,
H-Tronic, Germany). These were converted and saved with a
curve performance software (RealView3.0, Abacom, Germany).
The RealView data were transferred to Excel (Microsoft Office
Software) for further processing.
Another catheter was inserted in an ear vein for
administration of either CRP (3.5 mg/kg body weight
corresponding to 50µg/mL blood volume) or bovine
serum albumin (BSA) as control. CRP or BSA, each diluted
in application buffer (15 mg/mL), were slowly injected
intravenously (volume ranging from 0.44 to 1.17mL over
1min) followed by a flush of 0.9% saline. Seven animals received
treatment with CRP and five of these received treatment
with BSA as a control protein either 1 h after or before CRP
application. To rule out individual animal effects, control
and CRP application was performed and compared in the
same rabbits. Blood samples were taken before and after
the experiment.
The first animal died unexpectedly and immediately after
the intravenous injection of CRP. It is to be assumed that the
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administration was too fast. The following rabbits were injected
more slowly.
ELISA for Human CRP
Rabbit blood samples were collected in serum tubes. Serum
was separated with centrifugation and frozen for later analysis.
A 96-well-ELISA-plate (Corning, USA) was coated with
9µg/mL polyclonal rabbit-anti-human CRP-antibody (Dako,
Denmark). After incubation, wells were washed (0.1% Tween
in PBS) and blocked with a 0.1% casein-solution. Samples
were diluted in 5mM EDTA-solution and incubated in
coated wells. Horseradish-peroxidase-conjugated rabbit-anti-
humanCRP antibodies (14 ng/mL) were added. After addition
and incubation of peroxidase substrate (tetramethylbenzidine,
SigmaAldrich, USA) reaction was stopped by 1M sulphuric
acid. Finally, photometric measurement followed at 450 nm
and 620 nm (reference) with an ELISA-reader (Sunrise, Tecan,




For the assays on Ca2+ signaling we used two different cell
lines. CHO-α1A is a clonal cell line derived from Chinese
hamster ovaries stably exhibiting overexpression of the human
α1A-adrenergic receptor (α1A-AR) with efficient coupling to
intracellular calcium (Ca2+i ). DU-145 is a clonal tumor cell line
derived from human prostate cancer that expresses different
GPCRs such as α1-AR and β-ARs. CHO-α1A cells were cultivated
in Ham’s F12 medium supplemented with glutamine and DU-
145 cells in RPMI-1640 medium, respectively, with the addition
of 10% fetal calf serum (FCS) and 1% penicillin/streptomycin
solution at 37◦C and 5% CO2 saturation. CHO-α1A and DU-145
cell lines were kindly provided byDr. GerdWallukat, formerMax
Delbrueck Center for Molecular Medicine, Berlin.
To observe and quantify the real-time changes of cytosolic
Ca2+ alterations the fluorescent dye Fura-2 and a Victor
X2 fluorescence multiplate reader (Perkin Elmer, Langenfeld,
Germany) equipped with an injector unit were used. In light
diminished conditions, cells were treated with 5µM Fura-2
(Merck Biosciences, Bad Soden, Germany) for 45min at 37◦C.
Cells were washed and incubated in HBSS-HEPES (Hanks’
Balanced Salt Solution modified with 10mM HEPES) plus
2,5mM Probenecid for another 30min before transfer to the
microplate reader (26). Real-time fluorescence measurements
were recorded every 1.65 s over a period of 150 s at an
alternating excitation wavelength of 340 nm and 380 nm and
emission wavelength of 510 nm. The intracellular free Ca2+
concentration can be obtained from the ratio of emission
after stimulation at both wavelengths. In order to compare
the Ca2+ signals of all experiments, the baseline values were
subtracted and the difference value (1Ca2+i ) was plotted
against time.
To determine the effect of CRP in comparison to that
of pharmacological adrenergic receptor agonists, we used
phenylephrine (PE), a selective α1-AR agonist and isoprenaline
(isoproterenol, ISO), a non-selective β-AR agonist. At the
beginning, the baseline value was measured and after 30 s
CRP, PE or ISO was added. All conditions were performed in
technical duplicates.
RESULTS
Experiment 1: Rapid Drop of Blood
Pressure in Rabbits After CRP Injection
(in vivo)
To determine whether hCRP has a direct effect on the resting
heart rate and blood pressure of rabbits, animals were injected
with hCRP (3.5 mg/kg) without further treatment and the HR
and ABP were monitored over time. At the beginning and end of
each experiment, blood samples were collected and analyzed by
a specific human CRP ELISA. No human CRP was detectable in
rabbits prior to CRP injection (data not shown). About 1 h after
injection, the mean circulating human CRP concentration was 45
± 9.1 mg/L (range of 7 animals: 35 to 63 mg/L).
Immediately after intravenous injection of CRP, we observed
a surprisingly drastic drop in ABP, while the HR stayed the
same (Figure 1A). Control animals, which were injected with
the same amount of BSA solution, showed no changes in ABP
or HR (Figure 1B). Figure 1C compares the effect shown in
Figures 1A,B as area between the curve and the zero line. Within
the first 6min after i.v. injection the area was significantly
larger in animals treated with CRP compared to control
animals. Representative courses of both groups are depicted in
Figures 1D,E and show the absolute values of ABP andHR. Here,
the representative animal injected with CRP exhibited a drop in
blood pressure from 54 to 30 mmHg at its lowest point (at 4min
= 2min after injection), which did not recover within 10min
after injection, while the HR did not counteract at all as would
be normally expected.
The experimental setup as such, including the anesthesia and
the catheters used, had no effect on the heart rate and lowered
blood pressure only slightly over time (Supplemental Figure 1).
Experiment 2: Characterization of
CRP-Induced Calcium-Signaling in
Epithelial Cells (in vitro)
Our next step was to investigate the influence of CRP on
adrenoceptor signaling in vitro. As part of the group of GPCRs,
these receptors have different pathways of signal transduction,
which all use Ca2+ as second messenger. We therefore examined
whether CRP affects calcium influx in vitro in two different cell
lines expressing either exclusively α1A-AR (CHO-α1A) or both α
and β-ARs (DU-145).
In the first assay, the effect of CRP on the intracellular free
calcium concentration ([Ca2+]i) was investigated in comparison
to the adrenoceptor stimulation by agonists. The maximum
effective concentration of PE was 5µM and of ISO 1µM,
respectively. CRP was applied to reach a final concentration
of 50µg/mL. As control protein, we used human serum IgG
(50 µg/mL).
Figures 2A,B illustrate CRP-induced increase in [Ca2+]i
in CHO-α1A and DU-145 cells compared with the full
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FIGURE 1 | (A–E) Human CRP injection triggers rapid drop in blood pressure in rabbits. (A,B) 5 (A) or 7 (B) rabbits were monitored for their mean arterial blood
pressure (ABP) and heart rate (HR). Data points were recorded every 20ms and are plotted for every second. After 2min, 3.5 mg/kg hCRP or BSA as control were
injected intravenously. Graphs depict relative change in mean ABP (gray) and HR (black) over time ± SEM (standard error of the mean) as lighter shade envelope. The
difference between placebo (BSA) and CRP-infusion group is highly significant (Fisher’s exact test: ***p < 0.001). (C) Calculation of the area between the curve of ABP
and the zero line (Area Over the Curve = AOC) depicted in (A,B) between 2 and 8min. Mean area of 7 (hCRP) or 5 (ctrl) animals ± SEM. Control area is significantly
smaller than hCRP treated area. *** < 0.001 after Student’s t-test. (D,E) Representative animals from the control group (D) or the hCRP group (E) with absolute values
of HR (black) and ABP (gray) over the time course of 12min.
adrenoceptor agonist effect of PE and ISO. In both cell lines,
CRP elicited increases in [Ca2+]i, consisting of an initial transient
phase followed by a sustained phase. In CHO-α1A cells, CRP-
induced [Ca2+]i showed a two-thirds lower and slower increase
compared to PE, but then remained stable over the entire
measurement period. In DU-145 cells, the increase of [Ca2+]i
after CRP application was higher than after PE and ISO,
and approximately as fast. The subsequent maintenance phase
decreased slowly, comparable to the effect of PE. The application
of human serum control IgG had little or no effect on [Ca2+]i in
both cell lines (Figure 2C).
To investigate a dose-dependent effect of CRP on [Ca2+]i,
in a second assay CRP was applied in three different
final concentrations (25, 50, and 100µg/mL). Figures 3A,B
demonstrate that the CRP-induced increase of [Ca2+]i in both
cell lines was depending on the CRP concentration. A high CRP
concentration caused a faster and higher [Ca2+]i increase.
In a third assay, the effect of different sequential applications
of CRP and adrenoceptor agonists on [Ca2+]i was investigated.
Therefore, either CRP (50µg/mL) was added 70 s after full
adrenoceptor stimulation with PE or ISO or the agonists were
added after CRP stimulation. This was performed in order to
gain insight whether the CRP induced calcium influx is triggered
via adrenoceptor activation or whether it uses independent
mechanisms. Under the influence of an agonist, a receptor is
desensitized in order to avoid overstimulation of a cell by signal
molecules and no further [Ca2+]i increase was expected. The
effect of sequential application of CRP following PE/ISO or
vice versa is shown in Figure 4 for both cell lines. In CHO-
α1A cells, the application of CRP following PE did not lead
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FIGURE 2 | (A–C) Change of intracellular calcium concentration ([Ca2+]i) after CRP application, depicted as 1Ca
2+
i over the time. (A–C) Arrow indicates application
of either CRP (final concentration 50µg/ml), control IgG (final concentration 50µg/ml), phenylephrine (PE, final concentration 5µM) or isoprenaline (ISO, final
concentration 1µM). Graphs depict measured ratio 340/380 nm every 1.65 s. Data are representative of three experiments. (A) In CHO-α1A cells, 1Ca2+i rises 20 s
after CRP application to a maximum of approximately 0.27, followed by a persistent plateau. For comparison: the application of α1-AR agonist PE leads after 10 s to a
1Ca2+i maximum of ∼0.78, followed by a decrease. (B) In DU-145 cells, 18 s after CRP application 1Ca
2+
i reaches a maximum of approximately 0.83. PE and the
β1-AR agonist ISO lead to a 1Ca2+i maximum of ∼0.67 after 15 s (PE) and ∼0.48 after 18 s (ISO), respectively. (C) No (CHO-α1A) or only a slight (DU-145) increase
was observed after application of human serum IgG as control protein.
to a further increase of [Ca2+]i, but the decline of [Ca
2+]i
was stopped and stayed upregulated on a steady level, while
the stimulation with PE after CRP application additionally
increased [Ca2+]i (Figure 4A). In DU-145 cells, CRP following
PE additionally mobilized Ca2+, and PE following CRP also
triggered an additional increase of [Ca2+]i (Figure 4B). When
CRP was given after ISO, the increase in [Ca2+]i was even higher
and remained on a sustained plateau, whereas application of ISO
after CRP also enhanced [Ca2+]i but only slightly (Figure 4C).
Last, we wanted to see whether the combination of the two
different agonists inducing complete adrenoceptor activation of
their respective adrenoceptor increases [Ca2+]i. Stimulation of
DU-145 cells with ISO led to a brief increase in [Ca2+]i, which
was followed by a decrease and a strong increase after subsequent
PE application. Vice versa application differed, as the PE-induced
increase stayed upregulated and was again enhanced slightly by
ISO stimulation (Figure 4D).
DISCUSSION
The study was designed to investigate a possible influence of
CRP in vivo on a healthy organism, respectively, in vitro on vital
cell lines that are neither damaged, necrotic nor apoptotic. To
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FIGURE 3 | (A,B) Dose-dependent effect of CRP on [Ca2+]i. In both cell lines, a higher concentration of the applied CRP leads to a faster and higher increase of
[Ca2+]i. (A,B) Arrow indicates application of CRP. Graphs depict measured ratio 340/380 nm every 1.65 s. Data are representative of three experiments. A
4-parameter sigmoidal logistic fit curve was fit to demonstrate the typical dose response kinetics. (A) In CHO-α1A cells, CRP was applied at different final
concentrations (25, 50, or 100µg/ml). The maximum 1Ca2+i was 0.08 for 25µg/ml CRP, 0.18 for 50µg/ml CRP and 0.28 for 100µg/ml CRP. The half-maximum
Ca2+ signal, which corresponds to the inflection point of the logistic regression curve, was reached after 10.9/9.3/8.1 s (CRP 25/50/100µg/ml). (B) In DU-145 cells,
CRP was applied at different final concentrations (25, 50 or 100µg/ml). The maximum 1Ca2+i was 0.34 for 25µg/ml CRP, 0.61 for 50µg/ml CRP and 0.82 for
100µg/ml CRP. The half-maximum Ca2+ signal was reached after 11.3/9.3/8.2 s (CRP 25/50/100µg/ml).
prevent possible side effects of commercial CRP solutions (27)
we purified CRP by ourselves from pooled frozen human plasma.
The purified native human CRP is almost completely present in
its natural pentameric form.
The intravenous injection of CRP in rabbits has a minimal
direct influence on the heart rate (HR) but a dramatic effect
on the arterial blood pressure (ABP) as shown in Figure 1.
The intravenous administration of CRP in anesthetized rabbits
resulted in an immediate drop in blood pressure, while HR
remained the same and did not counteract as we would expect.
Normally, a drop in blood pressure would lead to an activation of
the sympathetic nervous system by suppressing the baroreceptor
reflex and thus to an increase in heart rate. The physiological
mechanisms behind our observations are therefore not clear. It
took about 15min for ABP to return to baseline.
Despite all caution in the first animal, the intravenous
injection of CRP was probably too fast. The animal died
immediately, we suspect due to a drastic drop in blood pressure
caused by the effect of CRP. The administration of pure solution
buffer containing bovine serum albumin (BSA) as a protein
control showed no effect.
Previous studies on the direct effects of human CRP on
the cardiovascular system in vivo recorded changes after a few
minutes at the earliest. In rats, for example, the administration
of 20 mg/kg CRP had no effect on blood pressure compared
to control animals, but ABP was measured only every 15min
after administration (28). In contrast, we measured the acute
effect of CRP administration at very small intervals right from
the time of injection. Since the observed effect in rabbits reached
its peak about 3min after CRP injection and then declined back
to baseline, measurements after 15min would probably not have
shown any changes.
Another study, directly administering recombinant CRP into
human subjects, also showed no changes in hemodynamic
parameters and vasodilator capacity (29). However, CRP serum
levels increased to only 30 mg/L after infusion. Further,
hemodynamic parameters and vascular reactivity were measured
6 h after CRP infusion not accounting for acute effects, but
rather inflammatory-mediated mechanisms. Also, in a study by
Bisoendial et al., in which healthy human volunteers were given
recombinant CRP, the CRP level increased only up to 23.9 mg/L
and inflammatory blood parameters were determined at the
earliest after 1 h (30). Nevertheless, they observed a systemic
inflammatory response and stimulation of the coagulation
cascade by administration of CRP.
Lane et al. similarly investigated the effects of a single
intravenous bolus of natural human CRP, but in seven volunteers
over a period of 0.5 h to 10 days (31). They found no clinically
significant changes, neither physical nor hematological. In
contrast, we investigated the effect of human CRP on rabbits,
which differ significantly from humans in both body size and
metabolic rate. In addition, the rabbits were anesthetized while
the human probands were not. The drastic immediate effect,
which started 2min after the infusion, could be due to a faster
availability of the infused CRP in a smaller organism.
To our knowledge, this study is the first to demonstrate
a direct and acute effect of CRP on blood pressure in vivo,
which could account for the hardly controllable hemodynamic
parameters of patients with excessive CRP levels and hint toward
a molecular interaction of CRP with the adrenergic system.
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FIGURE 4 | (A–D) Effect of sequential application of PE or ISO and CRP on [Ca2+]i. (A–D) Arrows indicate different applications of either CRP (final concentration
50µg/ml), phenylephrine (PE, final concentration 5µM) or isoprenaline (ISO, final concentration 1µM) in sequential combinations apparent from legends. 2nd
application was performed after 100 s of measurement, thus 70 s after 1st application. Graphs depict measured ratio 340/380 nm every 1.65 s. Data are
representative of three experiments.
Subsequently, we investigated in vitro whether CRP affects
adrenergic receptors, since these are mainly found on smooth
muscle cells of the blood vessels and on cardiomyocytes and are
thus significantly involved in the regulation of blood pressure.
CHO-α1A cells are transfected epithelial cells that express only
α1A-AR (32). DU-145 prostate tumor cells express a number of
different GPCRs such as α1−, β1−, and β2-ARs and H1-histamine
receptors (33, 34). Both cell lines show efficient coupling to Ca2+
of the adrenoceptors and can therefore be used for investigation
of this signal transduction pathway.
We observed that CRP triggered calcium signaling in both cell
lines (Figure 2). This increase in [Ca2+]i was dose-dependent,
i.e., the higher the applied CRP concentration, the more and
faster Ca2+ was mobilized in the cell (Figure 3). To our
knowledge, this is the first time to show a direct effect of CRP
on cellular calcium signaling.
Further, the CRP induced calcium influx was comparable in
intensity and duration to the stimulation with the adrenoceptor
agonists PE and ISO.
In order to investigate which molecular mechanism CRP
uses to directly affect calcium levels, we sequentially applied
adrenoceptor agonists and CRP in different combinations. After
desensitizing α-AR or β-ARs with PE and ISO, respectively, CRP
still triggered an additional calcium increase in DU-145 cells
(Figures 4B,C). This was not the case in CHO-α1A cells, in which
after PE stimulation the declining calcium signal did not rise
again with the CRP stimulus but only remained on a plateau
(Figure 4A). Vice versa, both agonists additionally mobilized
calcium after the CRP induced calcium rise in both cell lines.
Interestingly, after desensitization of adrenoceptors,
CRP managed to increase intracellular calcium levels more
dramatically than PE or ISO in DU-145 cells (Figure 4D).
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This hints toward a molecular mechanism independent of
adrenoceptor activation. On the other hand, in CHO-α1A cells,
CRP did not trigger calcium influx after desensitization of
α-ARs, which in this cell line is the only expressed adrenoceptor.
Potentially, CRP activates all types of adrenoceptors, and can
therefore not trigger more calcium signaling in CHO-α1A cells,
as no β-ARs are expressed.
The well-established function of CRP as protein of the
innate immune system is the elimination of cells via activation
of complement triggered by binding of CRP to special
phosphocholine components. Phosphocholine is e.g., accessible
to CRP on the surface of pathogens (C-Polysaccharide) or in the
plasma membrane of damaged or necrotic cells, which exhibit
lysophosphatidylcholine (35, 36). We show that, additionally,
CRP seems to be able to act on healthy cells and increase
intracellular free Ca2+. The underlying molecular mechanism for
that is unclear and using different combinations of adrenoceptor
agonists and CRP stimulation gave preliminary results, which
hint toward an adrenoceptor-independent pathway. However,
it is still possible that CRP engages adrenoceptors directly
as the calcium influx kinetics resemble those triggered by
adrenoceptor agonists. The additive effect of CRP on PE and ISO
could potentially either be explained by activating the saturated
adrenoceptors differently than the agonists or by the hypothesis
that CRP engages both α- and β-ARs, while the agonists were
specific for only one type.
Further, CRP could interfere with their desensitization,
perhaps it might even affect other GPCRs. The mechanism
remains obscure and further research should follow to
understand this effect in detail.
Several in vitro studies on endothelial cells of different
species suggest a damaging effect of CRP on the cardiovascular
system by influencing the endothelial nitric oxide (NO) synthase
(eNOS) in expression and function. CRP uncouples eNOS,
resulting in increased superoxide production and reduced NO
synthesis, which can lead to vasodilatation disorders (37–41).
eNOS is activated by an increase in the [Ca2+]i and the
association of a Ca2+/calmodulin complex with the enzyme (42).
Thus, endothelial NO production is enhanced which induces
vasodilatation in the organism (43). Our in vitro findings appear
to be reflected by the drastic drop of blood pressure after CRP
injection in our in vivo experiments. By a hitherto undiscovered
mechanism, CRP induces Ca2+ signaling, which may have led
to vasodilatation due to increased NO production via activation
of eNOS. This seems to outweigh the eNOS uncoupling effect of
CRP. Theremight be a dose dependence. Further studies focusing
on the impact of CRP on the NO system might be promising.
CONCLUSION
The findings of our animal experiments suggest a direct systemic
influence of CRP in rabbits in vivo, resulting in a drastic drop
of blood pressure shortly after the intravenous injection. The
organism did not counteract this effect by upregulating the
heart rate as expected. On the cellular level, a corresponding
effect can be found. The application of CRP modulates the
calcium signaling to a dose-dependent extent. The increase
in intracellular calcium concentration triggered by CRP is
potentially mediated by adrenoceptors, but could also use a
different molecular mechanism.
STUDY LIMITATIONS
In order to obtain a first indication if CRP has a direct effect on
the circulatory system of rabbits in vivo, only few animals were
used in the experiments for ethical reasons. Further, although
the biological role and properties of CRP are comparable, other
species differences could explain why this effect has not been
demonstrated in humans so far. The in vitro experiments have
been performed with transfected cells (CHO-α1A) or with cells
not yet precisely characterized in regard to GPCRs (DU-145). It
remains to be investigated if the observations can also be reflected
in humans.
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